Mereo BioPharma Group plc (LON: 0A9G)

London flag London · Delayed Price · Currency is GBP · Price in USD
2.969
+0.024 (0.81%)
At close: Jan 22, 2025
-3.92%
Market Cap 367.25M
Revenue (ttm) 746.10K
Net Income (ttm) -33.81M
Shares Out n/a
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,876
Average Volume 2,572
Open 3.010
Previous Close 2.945
Day's Range 2.918 - 3.010
52-Week Range 1.796 - 4.001
Beta 0.97
RSI 36.22
Earnings Date Mar 28, 2025

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 33
Stock Exchange London Stock Exchange
Ticker Symbol 0A9G
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.